Search

Your search keyword '"Voorham, R."' showing total 6 results
Start Over Author "Voorham, R."
6 results on '"Voorham, R."'

3. Global impact of the COVID-19 pandemic on cytopathology practice: Results from an international survey of laboratories in 23 countries

Author

Vigliar, E., Cepurnaite, R., Alcaraz-Mateos, E., Ali, S.Z., Baloch, Z.W., Bellevicine, C., Bongiovanni, M., Botsun, P., Bruzzese, D., Bubendorf, L., Büttner, R., Canberk, S., Capitanio, A., Casadio, C., Cazacu, E., Cochand-Priollet, B., D’Amuri, A., Eloy, C., Engels, M., Fadda, G., Fontanini, G., Fulciniti, F., Hofman, P. (Pieter), Iaccarino, A., Ieni, A., Jiang, X.S., Kakudo, K., Kern, I., Kholova, I., Liu, C., Lobo, A., Lozano, M.D., Malapelle, U., Maleki, Z., Michelow, P., Musayev, J., Özgün, G., Oznur, M., Peiró Marqués, F.M., Pisapia, P., Poller, D., Pyzlak, M., Robinson, B., Rossi, E.D., Roy-Chowdhuri, S., Saieg, M., Savic Prince, S., Schmitt, F.C., Javier Seguí Iváñez, F., Štoos-Veić, T., Sulaieva, O., Sweeney, B.J., Tuccari, G., van Velthuysen, M.L., VanderLaan, P.A., Vielh, P., Viola, P., Voorham, R., Weynand, B., Zeppa, P., Faquin, W.C., Pitman, M.B., Troncone, G., Vigliar, E., Cepurnaite, R., Alcaraz-Mateos, E., Ali, S.Z., Baloch, Z.W., Bellevicine, C., Bongiovanni, M., Botsun, P., Bruzzese, D., Bubendorf, L., Büttner, R., Canberk, S., Capitanio, A., Casadio, C., Cazacu, E., Cochand-Priollet, B., D’Amuri, A., Eloy, C., Engels, M., Fadda, G., Fontanini, G., Fulciniti, F., Hofman, P. (Pieter), Iaccarino, A., Ieni, A., Jiang, X.S., Kakudo, K., Kern, I., Kholova, I., Liu, C., Lobo, A., Lozano, M.D., Malapelle, U., Maleki, Z., Michelow, P., Musayev, J., Özgün, G., Oznur, M., Peiró Marqués, F.M., Pisapia, P., Poller, D., Pyzlak, M., Robinson, B., Rossi, E.D., Roy-Chowdhuri, S., Saieg, M., Savic Prince, S., Schmitt, F.C., Javier Seguí Iváñez, F., Štoos-Veić, T., Sulaieva, O., Sweeney, B.J., Tuccari, G., van Velthuysen, M.L., VanderLaan, P.A., Vielh, P., Viola, P., Voorham, R., Weynand, B., Zeppa, P., Faquin, W.C., Pitman, M.B., and Troncone, G.

Abstract

BACKGROUND: To the authors’ knowledge, the impact of the coronavirus disease 2019 (COVID-19) pandemic on cytopathology practices worldwide has not been investigated formally. In the current study, data from 41 respondents from 23 countries were reported. METHODS: Data regarding the activity of each cytopathology laboratory during 4 weeks of COVID-19 lockdown were collected and compared with those obtained during the corresponding period in 2019. The overall number and percentage of exfoliative and fine-needle aspiration cytology samples from each anatomic site were recorded. Differences in the malignancy and suspicious rates between the 2 periods were analyzed using a meta-analytical approach. RESULTS: Overall, the sample volume was lower compared with 2019 (104,319 samples vs 190,225 samples), with an average volume reduction of 45.3% (range, 0.1%-98.0%). The percentage of samples from the cervicovaginal tract, thyroid, and anorectal region was significantly reduced (P < .05). Conversely, the percentage of samples from the urinary tract, serous cavities, breast, lymph nodes, respiratory tract, salivary glands, central nervous system, gastrointestinal tract, pancreas, liver, and biliary tract increased (P < .05). An overall increase of 5.56% (95% CI, 3.77%- 7.35%) in the malignancy rate in nongynecological samples during the COVID-19 pandemic was observed. When the suspicious category was included, the overall increase was 6.95% (95% CI, 4.63%-9.27%). CONCLUSIONS: The COVID-19 pandemic resulted in a drastic reduction in the total number of cytology specimens regardless of anatomic site or specimen type. The rate of malignancy increased, reflecting the prioritization of patients with cancer who were considered to be at high risk. Prospective monitoring of the effect of delays in access to health services during the lockdown period is warranted.

Published
2020
Full Text
View/download PDF

4. Global impact of the COVID-19 pandemic on cytopathology practice: Results from an international survey of laboratories in 23 countries

Author

Vigliar, E, Cepurnaite, R, Alcaraz-Mateos, E, Ali, SZ, Baloch, ZW, Bellevicine, C, Bongiovanni, M, Botsun, P, Bruzzese, D, Bubendorf, L, Büttner, R, Canberk, S, Capitanio, A, Casadio, C, Cazacu, E, Cochand-Priollet, B, D’Amuri, A, Eloy, C, Engels, M, Fadda, G, Fontanini, G, Fulciniti, F, Hofman, P, Iaccarino, A, Ieni, A, Jiang, XS, Kakudo, K, Kern, I, Kholova, I, Liu, Chang, Lobo, A, Lozano, MD, Malapelle, U, Maleki, Z, Michelow, P, Musayev, J, Özgün, G, Oznur, M, Peiró Marqués, FM, Pisapia, P, Poller, D, Pyzlak, M, Robinson, B, Rossi, ED, Roy-Chowdhuri, S, Saieg, M, Savic Prince, S, Schmitt, FC, Javier Seguí Iváñez, F, Štoos-Vei?, T, Sulaieva, O, Sweeney, BJ, Tuccari, G, van Velthuysen, MLF (M. Loes), VanderLaan, PA, Vielh, P, Viola, P, Voorham, R, Weynand, B, Zeppa, P, Faquin, WC, Pitman, MB, Troncone, G, Vigliar, E, Cepurnaite, R, Alcaraz-Mateos, E, Ali, SZ, Baloch, ZW, Bellevicine, C, Bongiovanni, M, Botsun, P, Bruzzese, D, Bubendorf, L, Büttner, R, Canberk, S, Capitanio, A, Casadio, C, Cazacu, E, Cochand-Priollet, B, D’Amuri, A, Eloy, C, Engels, M, Fadda, G, Fontanini, G, Fulciniti, F, Hofman, P, Iaccarino, A, Ieni, A, Jiang, XS, Kakudo, K, Kern, I, Kholova, I, Liu, Chang, Lobo, A, Lozano, MD, Malapelle, U, Maleki, Z, Michelow, P, Musayev, J, Özgün, G, Oznur, M, Peiró Marqués, FM, Pisapia, P, Poller, D, Pyzlak, M, Robinson, B, Rossi, ED, Roy-Chowdhuri, S, Saieg, M, Savic Prince, S, Schmitt, FC, Javier Seguí Iváñez, F, Štoos-Vei?, T, Sulaieva, O, Sweeney, BJ, Tuccari, G, van Velthuysen, MLF (M. Loes), VanderLaan, PA, Vielh, P, Viola, P, Voorham, R, Weynand, B, Zeppa, P, Faquin, WC, Pitman, MB, and Troncone, G

Published
2020

5. Global impact of the COVID‐19 pandemic on cytopathology practice: Results from an international survey of laboratories in 23 countries

Author

Pio Zeppa, Gonca Özgün, Eugeniu Cazacu, Franco Fulciniti, Alessandro D’Amuri, Izidor Kern, Philippe Vielh, Reinhard Büttner, Jamal Musayev, Meltem Öznur, Chiara Casadio, Brenda Sweeney, Marianne Engels, Tajana Štoos-Veić, William C. Faquin, Eduardo Alcaraz-Mateos, Birgit Weynand, Esther Diana Rossi, Béatrix Cochand-Priollet, Claudio Bellevicine, Zubair W. Baloch, Betsy Robinson, Paul A. VanderLaan, Fernando Schmitt, Anandi Lobo, Martha B. Pitman, Kennichi Kakudo, Antonio Ieni, Rima Cepurnaite, Sule Canberk, David N. Poller, Arrigo Capitanio, Marie Louise F. van Velthuysen, Dario Bruzzese, Giancarlo Troncone, Francisco Javier Seguí Iváñez, Pamela Michelow, Ivana Kholová, Pasquale Pisapia, Rinus Voorham, Michal Pyzlak, Lukas Bubendorf, Gabriella Fontanini, Umberto Malapelle, Guido Fadda, Pavlina Botsun, Oksana Sulaieva, Sinchita Roy-Chowdhuri, Catarina Eloy, Francisca Maria Peiró Marqués, Antonino Iaccarino, Chinhua Liu, Giovanni Tuccari, Mauro Saieg, Xiaoyin Sara Jiang, Elena Vigliar, Syed Z. Ali, Zahra Maleki, Maria D. Lozano, Massimo Bongiovanni, Patrizia Viola, Paul Hofman, Spasenija Savic Prince, Vigliar, E., Cepurnaite, R., Alcaraz-Mateos, E., Ali, S. Z., Baloch, Z. W., Bellevicine, C., Bongiovanni, M., Botsun, P., Bruzzese, D., Bubendorf, L., Buttner, R., Canberk, S., Capitanio, A., Casadio, C., Cazacu, E., Cochand-Priollet, B., D'Amuri, A., Eloy, C., Engels, M., Fadda, G., Fontanini, G., Fulciniti, F., Hofman, P., Iaccarino, A., Ieni, A., Jiang, X. S., Kakudo, K., Kern, I., Kholova, I., Liu, C., Lobo, A., Lozano, M. D., Malapelle, U., Maleki, Z., Michelow, P., Musayev, J., Ozgun, G., Oznur, M., Peiro Marques, F. M., Pisapia, P., Poller, D., Pyzlak, M., Robinson, B., Rossi, E. D., Roy-Chowdhuri, S., Saieg, M., Savic Prince, S., Schmitt, F. C., Javier Segui Ivanez, F., Stoos-Veic, T., Sulaieva, O., Sweeney, B. J., Tuccari, G., van Velthuysen, M. -L., Vanderlaan, P. A., Vielh, P., Viola, P., Voorham, R., Weynand, B., Zeppa, P., Faquin, W. C., Pitman, M. B., Troncone, G., Erasmus MC other, and Pathology

Subjects
Cancer Research, Biopsy, neoplasms, 0302 clinical medicine, Surveys and Questionnaires, Cytology, Pathology, Surveys and Questionnaire, coronavirus disease 2019 (COVID&#8208, malignancy rate, Societies, Medical, Gastrointestinal tract, Pathology, Clinical, medicine.diagnostic_test, stopnja malignosti, udc:616, Serous fluid, citopatologija, Fine-needle aspiration, Oncology, Biliary tract, 030220 oncology & carcinogenesis, coronavirus disease 2019 (COVID-19), Life Sciences & Biomedicine, Human, medicine.medical_specialty, fine&#8208, Urinary system, Biopsy, Fine-Needle, 030209 endocrinology & metabolism, Workload, Malignancy, cytopathology, fine-needle aspiration, needle aspiration, COVID-19, Communicable Disease Control, Humans, Laboratories, Hospital, SARS-CoV-2, Hospital, Clinical, coronavirus disease 2019, 03 medical and health sciences, novotvorbe, Medical, Internal medicine, medicine, coronavirus disease 2019 (COVID-19), cytopathology, fine-needle aspiration, malignancy rate, tankoigelna biopsija, Science & Technology, koronavirusna bolezen, business.industry, medicine.disease, patologija, Cytopathology, Fine-Needle, pathology, Laboratories, Societies, 19), business
Abstract

BACKGROUND: To the authors' knowledge, the impact of the coronavirus disease 2019 (COVID-19) pandemic on cytopathology practices worldwide has not been investigated formally. In the current study, data from 41 respondents from 23 countries were reported. METHODS: Data regarding the activity of each cytopathology laboratory during 4 weeks of COVID-19 lockdown were collected and compared with those obtained during the corresponding period in 2019. The overall number and percentage of exfoliative and fine-needle aspiration cytology samples from each anatomic site were recorded. Differences in the malignancy and suspicious rates between the 2 periods were analyzed using a meta-analytical approach. RESULTS: Overall, the sample volume was lower compared with 2019 (104,319 samples vs 190,225 samples), with an average volume reduction of 45.3% (range, 0.1%-98.0%). The percentage of samples from the cervicovaginal tract, thyroid, and anorectal region was significantly reduced (P < .05). Conversely, the percentage of samples from the urinary tract, serous cavities, breast, lymph nodes, respiratory tract, salivary glands, central nervous system, gastrointestinal tract, pancreas, liver, and biliary tract increased (P < .05). An overall increase of 5.56% (95% CI, 3.77%-7.35%) in the malignancy rate in nongynecological samples during the COVID-19 pandemic was observed. When the suspicious category was included, the overall increase was 6.95% (95% CI, 4.63%-9.27%). CONCLUSIONS: The COVID-19 pandemic resulted in a drastic reduction in the total number of cytology specimens regardless of anatomic site or specimen type. The rate of malignancy increased, reflecting the prioritization of patients with cancer who were considered to be at high risk. Prospective monitoring of the effect of delays in access to health services during the lockdown period is warranted. ispartof: CANCER CYTOPATHOLOGY vol:128 issue:12 pages:885-894 ispartof: location:United States status: published

Published
2020
Full Text
View/download PDF

6. Mismatch repair deficiency: how reliable is the two-antibody approach? A national real-life study.

Author

Vink-Börger E, den Bakker M, Voorham R, van Nederveen F, and Nagtegaal I

Subjects
Humans, Female, Middle Aged, Male, Aged, Endometrial Neoplasms diagnosis, Endometrial Neoplasms genetics, Adult, DNA-Binding Proteins, Biomarkers, Tumor, Immunohistochemistry methods, Neoplastic Syndromes, Hereditary diagnosis, Aged, 80 and over, MutL Protein Homolog 1 genetics, Brain Neoplasms, Colorectal Neoplasms diagnosis, Colorectal Neoplasms genetics, DNA Mismatch Repair, Mismatch Repair Endonuclease PMS2
Abstract

Aims: Traditionally, mismatch repair (MMR) status is determined by a panel of four antibodies (MLH1, PMS2, MSH2, MSH6). If all proteins are retained, cases are MMR proficient (pMMR), while loss of one or more proteins is indicative of MMR deficiency (dMMR). This approach has been challenged in favour of a two-antibody approach, using PMS2 and MSH6 as a first screening. Their retainment is deemed sufficient to declare cases pMMR. In this study we aim to verify the validity of the two-antibody approach., Methods and Results: We performed a nationwide study in colorectal cancer (CRC) and endometrial cancer (EC) diagnosed between 2016 and 2023, including 47,657 patients to evaluate the two-antibody approach. In 0.17% and 0.4% of cases of CRC and EC, respectively, dMMR cases would be missed with the two-antibody approach. Subgroup analyses pointed towards slightly increased miss rates in younger patients (under the age of 50 years) in both groups and identified special subtypes (signet ring cell carcinoma, medullary carcinoma, and mucinous carcinoma in CRC and clear cell carcinoma in EC) with increased miss rates. For these specific subgroups, a low threshold should be used for further testing. In case of ambiguous or heterogeneous staining patterns, four antibodies should be used., Conclusion: In general, the application of a two-antibody MMR testing strategy does not lead to considerable failure of dMMR identification and saves costs., (© 2024 The Author(s). Histopathology published by John Wiley & Sons Ltd.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results